Virtual Seminar: Dissecting Toxicities of Immune Checkpoint Inhibitors
Douglas Johnson, M.D., MSCI
Associate Professor of Medicine
Clinical Director, Melanoma Program
Ingram Cancer Center
Vanderbilt University
Virtual Pioneers in Biomedical Research Seminar: Dissecting Toxicities of Immune Checkpoint Inhibitors
Nov. 19, 2021
11:00 a.m. to 12:00 p.m.
Archived video
About this Seminar
Anti-PD-1 therapy has dramatically altered cancer treatments, but many unanswered questions remain. First, the need for more accurate biomarkers to provide clues to the pathogenesis of response and resistance, and to more accurately assign patients to effective treatment remains a key unmet need. Tumor cell expression of MHC class II and tumor mutational burden are two potential markers of response. Second, patients treated with anti-PD-1, especially when used in combination, frequently experience severe immune-related toxicities. Identifying patients at risk, clinically phenotyping clinical events, and determine effective treatment strategies remain unmet needs. In this presentation, Dr. Johnson will discuss his lab's work in identifying anti-PD-1 biomarkers, particularly focusing on MHC-II and tumor mutational burden, and in characterizing anti-PD-1 toxicities.
Additional Details
This is a free event hosted by the Fralin Biomedical Research Institute and co-sponsored by the institute's Cancer Research Group. The Pioneers in Biomedical Research Seminar Series, which runs annually from September to May, has featured leading biomedical researchers from throughout the country since the program began in 2012. The lectures are also open to all members of the Virginia Tech community including graduate students, undergraduates, faculty, and staff, as well as the public.
You May Also Be Interested In...
-
Home Item
The Bitter Truth: Alcohol Use and Its Effects on Chemosensory Function , homeOct. 3, 2025, 11:00 a.m. | Paule Valery Joseph, Ph.D., Lasker Clinical Research Scholar, NIH Distinguished Scholar; Acting Chief, Section of Sensory Science and Metabolism Unit, Co-Director of the National Smell and Taste Center, National Institute on Deafness and Other Communication Disorders; National Institute of Alcohol Abuse and Alcoholism, National Institutes of Health | Co-Sponsored by the Fralin Biomedical Research Institute Center for Health Behaviors Research and Addiction Recovery Research Center
-
Home Item
Organization and Control of Hippocampal Networks , homeOct. 17, 2025, 11:00 a.m. | Ivan Soltesz, Ph.D., James R. Doty Professor of Neurosurgery and Neurosciences, Stanford University | Co-Sponsored by the Fralin Biomedical Research Institute Center for Neurobiology Research
-
Home Item
Maury Strauss Distinguished Public Lecture , homeOct. 30, 2025, 5:30 p.m. (Reception at 5 p.m.) | Jennifer Munson, Ph.D., Professor and Director, Cancer Research Center — Roanoke, Fralin Biomedical Research Institute; Professor, Department of Biomedical Engineering and Mechanics, Virginia Tech College of Engineering | Maury Strauss Distinguished Public Lecture
-
Home Item
Thinking the Right Thoughts , homeOct. 31, 2025, 11 a.m. | Nathaniel Daw, Ph.D., Professor, Computational and Theoretical Neuroscience, Department of Psychology, Princeton University | Co-Sponsored by the Fralin Biomedical Research Institute Center for Human Neuroscience Research
-
Home Item
Maury Strauss Distinguished Public Lecture , homeNov. 6, 2025, 5:30 p.m. (Reception at 5 p.m.) | Teresa Lambe, Ph.D., OBE, Calleva Head of Vaccine Immunology, Professor of Vaccinology and Immunology, University of Oxford | Maury Strauss Distinguished Public Lecture
-
Home Item
Understanding Vascular Morphogenesis and Morphology: Live Insights from Zebrafish , homeNov. 21, 2025, 11:00 a.m. | Arndt F. Siekmann, Ph.D., Associate Professor, Cell and Developmental Biology, Perelman School of Medicine, University of Pennsylvania | Co-Sponsored by the Center for Vascular and Heart Research, Fralin Biomedical Research Institute